The TATTON trial is an international multi-arm phase 1 study; it was the first to evaluate the dual inhibition of osimertinib and savolitinib in patients with EGFR-mutated advanced NSCLC who experienced disease progression after EGFR-TKI therapy [70,74,75,76]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.